Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Metolazone · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Metolazone Tablets 10 mg |
| 2 | ACTIVE_COMPARATOR | Zaroloxyn® Tablets 10 mg |
| Name | Type | Description |
|---|---|---|
| Metolazone Tablets 10 mg | DRUG | 10mg, single dose fasting |
| Zaroloxyn® Tablets 10 mg | DRUG | 10mg, single dose fasting |
| Metolazone Tablets 5 mg | DRUG | 2x5mg, single dose fasting |
| Zaroloxyn® Tablets 5 mg | DRUG | 2x5mg, single dose fasting |
| Metolazone Tablets 2.5 mg | DRUG | 4x2.5mg, single dose fasting |
| Zaroloxyn® Tablets 2.5 mg | DRUG | 4x2.5mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older 2. Sex: Male and/or non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum b-human chorionic gonadotropin (β-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening pr...
Metolazone is a small molecule drug developed by Viatris Inc. (ticker VTRS). It is an inhibitor of SLC12A3 and is currently in Phase 1 clinical development. Its therapeutic area is classified as Other, and the specific indications being studied are undisclosed.
Metolazone targets SLC12A3 and acts as an inhibitor of this target. SLC12A3 is a sodium chloride cotransporter. By inhibiting SLC12A3, Metolazone affects sodium reabsorption. This mechanism underlies its pharmacological activity as a small molecule therapeutic agent.
Metolazone is developed by Viatris Inc., which trades under the ticker symbol VTRS. Viatris is the company responsible for the development program. The drug is formulated as Metolazone Tablets in 2.5 mg, 5 mg, and 10 mg strengths.
Metolazone is in Phase 1 clinical development. It is an investigational drug and is not approved. Three Phase 1 trials have been completed, with no active trials currently ongoing. The completed trials enrolled a total of 160 participants across the studies.
Metolazone has been studied in three completed Phase 1 trials: NCT00650195, NCT00649181, and NCT00649051. These were fasting studies comparing Metolazone Tablets at 10 mg, 5 mg, and 2.5 mg against Zaroloxyn Tablets at matching strengths. All trials enrolled healthy volunteers in the United States.